Table 1.
Characteristics of study participants at first clinical visit
| N | 6,223 |
| Age (y) | 68.82 (8.85) |
| Gender (% women) | 3,681 (59.2) |
| Time before diagnosis/last visit (y) | 13.75 (6.55) |
| BMI (kg/m2) | 26.24 (3.70) |
| Waist circumference (cm) | 90.15 (11.10) |
| Systolic blood pressure (mm Hg) | 138.54 (22.00) |
| Diastolic blood pressure (mm Hg) | 73.82 (11.44) |
| Total cholesterol (mmol/L) | 5.83 (0.99) |
| LDL cholesterol (mmol/L) | 3.76 (0.91) |
| Triglycerides (mmol/L) | 1.49 (0.71) |
| HDL cholesterol (mmol/L) | 1.41 (0.40) |
| Glucose (mmol/L) | 5.68 (0.93) |
| Insulin (pmol/L) | 78.68 (61.44) |
| HOMA‐IR (units) | 123.54 (119.42) |
| HOMA ‐%B (units) | 1,642.76 (1,111.59) |
| Antihypertensive treatment (%) | 894 (17.0) |
| Lipid‐lowering medication (%) | 474 (13.6) |
| Current smoker (%) | 1,393 (23.1) |
Data are n (%) or mean (SD).
Fasting measurements of lipids and glycemic indices were available at third, fourth, and fifth visits of original Rotterdam Study cohort.
HDL, high‐density lipoprotein; HOMA‐%B, homeostatic model assessment‐beta cell function; HOMA‐IR, homeostatic model assessment‐insulin resistance; LDL, low‐density lipoprotein.